论文部分内容阅读
20 Septermber 2019Chronic myelomonocytic leukemia (CMML) is a clonal disease of bone marrow hematopoietic stem cells. Its incidence rate is approximately 1 to 2 in 100?000, and it occurs more commonly among the elderly, with amedian age of onset of 65–75 years. The survival period is 20 to 40 months, and 15% to 30% of patients experience progression into acute leukemia. However, CMML is not treated satisfactorily. We retrospectively analyzed the clinical features and efficacy of decitabine (DEC) combined with ruxolitinib (RUX) in six patients with CMML-1 and six patients with CMML-2.